{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:11:52Z","timestamp":1791231112145,"version":"4.1.0"},"reference-count":17,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>von Willebrand factor\u2013cleaving protease (ADAMTS13) cleaves von Willebrand factor (VWF) and regulates its physiologic function. To investigate the relation between ADAMTS13 activity and VWF, we compared ADAMTS13 activity with the VWF-related parameters VWF antigen (VWF:Ag), VWF collagen-binding activity (VWF:CBA), VWF-propeptide, proVWF, and VWF multimeric composition in 10 healthy volunteers and 3 patients with type 1 von Willebrand disease before and after infusing 0.3 \u03bcg\/kg desmopressin. The VWF-related parameters in the volunteers increased 60 minutes after start of infusion by 3.7-fold for VWF:Ag, 7.2-fold for propeptide, and 2.2-fold for VWF:CBA. Unusually large VWF multimers and traces of proVWF appeared. The ADAMTS13 activity decreased to about half the initial value. After 24 hours values returned to baseline. Patients with type 1 von Willebrand disease showed similar results. We conclude that the inverse correlation between ADAMTS13 and VWF-related parameters suggests a consumption of ADAMTS13 after the desmopressin-induced release of higher multimers of VWF.<\/jats:p>","DOI":"10.1182\/blood-2002-03-0814","type":"journal-article","created":{"date-parts":[[2003,1,15]],"date-time":"2003-01-15T16:05:10Z","timestamp":1042646710000},"page":"946-948","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":87,"title":["Changes in von Willebrand factor\u2013cleaving protease (ADAMTS13) activity after infusion of desmopressin"],"prefix":"10.1182","volume":"101","author":[{"given":"Rosemarie A.","family":"Reiter","sequence":"first","affiliation":[{"name":"From the Department of Clinical Pharmacology and the Department of Medicine 1, University of Vienna; Baxter Bio Science, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kno\u0308bl","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Pharmacology and the Department of Medicine 1, University of Vienna; Baxter Bio Science, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Varadi","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Pharmacology and the Department of Medicine 1, University of Vienna; Baxter Bio Science, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Turecek","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Pharmacology and the Department of Medicine 1, University of Vienna; Baxter Bio Science, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111612064310300_B1","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1073\/pnas.84.7.1955","article-title":"Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells.","volume":"84","author":"Wagner","year":"1987","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111612064310300_B2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","article-title":"Biochemistry and genetics of von Willebrand factor.","volume":"67","author":"Sadler","year":"1998","journal-title":"Annu Rev Biochem."},{"key":"2019111612064310300_B3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0037-1613992","article-title":"Impact, diagnosis and treatment of von Willebrand disease.","volume":"84","author":"Sadler","year":"2000","journal-title":"Thromb Haemost."},{"key":"2019111612064310300_B4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s002770050184","article-title":"Von Willebrand factor: molecular size and functional activity.","volume":"72","author":"Furlan","year":"1996","journal-title":"Ann Hematol."},{"key":"2019111612064310300_B5","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.","volume":"276","author":"Zheng","year":"2001","journal-title":"J Biol Chem."},{"key":"2019111612064310300_B6","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI112736","article-title":"Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.","volume":"78","author":"Moake","year":"1986","journal-title":"J Clin Invest."},{"key":"2019111612064310300_B7","first-page":"2244","article-title":"Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies.","volume":"59","author":"Oleksowicz","year":"1999","journal-title":"Canc Res."},{"key":"2019111612064310300_B8","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V98.9.2730","article-title":"Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.","volume":"98","author":"Mannucci","year":"2001","journal-title":"Blood."},{"key":"2019111612064310300_B9","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood."},{"key":"2019111612064310300_B10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood.V94.5.1637","article-title":"Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease.","volume":"94","author":"Turecek","year":"1999","journal-title":"Blood."},{"key":"2019111612064310300_B11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2516.1998.0040s3015.x","article-title":"The determination of von Willebrand factor activity by collagen binding assay.","volume":"4(suppl 3)","author":"Siekmann","year":"1998","journal-title":"Haemophilia."},{"key":"2019111612064310300_B12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1055\/s-0037-1616748","article-title":"Thrombin-mediated in vitro processing of pro-von Willebrand factor.","volume":"86","author":"Varadi","year":"2001","journal-title":"Thromb Haemost."},{"key":"2019111612064310300_B13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1055\/s-0037-1614780","article-title":"Assay of von Willebrand factor (VWF)-cleaving protease based on decreased collagen binding affinity of degraded VWF.","volume":"82","author":"Gerritsen","year":"1999","journal-title":"Thromb Haemost."},{"key":"2019111612064310300_B14","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/blood.V90.9.3555","article-title":"In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.","volume":"90","author":"Turecek","year":"1997","journal-title":"Blood."},{"key":"2019111612064310300_B15","first-page":"A42","article-title":"Kinetics of inhibitors of von Willebrand factor cleaving metalloprotease in three patients with severe thrombotic thrombocytopenic purpura.","volume":"81(suppl 1)","author":"Kno\u0308bl","year":"2002","journal-title":"Annals Hematol."},{"key":"2019111612064310300_B16","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1182\/blood.V88.8.2951.bloodjournal8882951","article-title":"Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginin vasopressin in humans.","volume":"88","author":"Borchiellini","year":"1996","journal-title":"Blood."},{"key":"2019111612064310300_B17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0038-1655973","article-title":"Acute von Willebrand factor secretion from endothelium in vivo: assessment through propeptide vVWF:AgII levels.","volume":"77","author":"Vischer","year":"1997","journal-title":"Thromb Haemost."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/3\/946\/1259615\/h80303000946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/3\/946\/1259615\/h80303000946.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T12:06:49Z","timestamp":1573906009000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/3\/946\/88853\/Changes-in-von-Willebrand-factorcleaving-protease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-03-0814","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2,1]]}}}